SCHEMBL25879875

SCHEMBL25879875

Cc1cc(O)c(C(C)C)nc1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.39
TRPA1 O75762 2/20 0.38
PTGS1 P23219 1/20 0.38
CACNA1C Q13936 1/20 0.38
KDM4E B2RXH2 4/20 0.34
HPGD P15428 3/20 0.34
HSD17B10 Q99714 2/20 0.34
ALDH1A1 P00352 2/20 0.34
MAPT P10636 2/20 0.34
PKM P14618 2/20 0.34
CYP1A2 P05177 2/20 0.34
CYP2D6 P10635 2/20 0.34
MAPK1 P28482 2/20 0.34
CYP3A4 P08684 1/20 0.34
G6PD P11413 1/20 0.34
CYP2C9 P11712 1/20 0.34
ALOX15 P16050 1/20 0.34
ALOX12 P18054 1/20 0.34
CYP2C19 P33261 1/20 0.34
CCR6 P51684 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13362540 0.79 NOS3 (0.31)
SCHEMBL27311076 0.76 TYR (0.44) ALDH1A1
SCHEMBL12316308 0.76 LMNA (0.33) LMNATRPA1CHRM1SLC6A2ADRA1A
SCHEMBL20285911 0.74 GLP1R (0.37) LMNA
SCHEMBL16231621 0.72 KDM4E (0.40) LMNAKDM4EHPGDHSD17B10ALDH1A1
SCHEMBL25879873 0.70 LMNA (0.39) LMNATRPA1PTGS1CACNA1CKDM4E
SCHEMBL22016865 0.69 SORT1 (0.33) TRPA1HPGDHSD17B10CYP1A2CYP2D6
SCHEMBL22165799 0.68 KDM4E (0.37) LMNAKDM4EHPGDHSD17B10ALDH1A1
SCHEMBL9832575 0.67
SCHEMBL13438489 0.67 KDM4E (0.30) LMNAKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227474-A1 COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING SKYHAWK THERAPEUTICS, INC. (US) 2023-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230227474-A1 COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING RBM17, SF3B1, SF3B5 LMNA 301/4885TRPA1 4691/4885PTGS1 3108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.